Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Chronic Inflammatory Bowel Disease | Research

LACC1 regulates changes in the intestinal flora in a mouse model of inflammatory bowel disease

Authors: Zheng-Yuan Xu, Jin-Chun Wang

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

The aim of this study was to explore the mechanism whereby LACC1 regulates the intestinal flora in a mouse model of inflammatory bowel disease (IBD).

Methods

C57BL/6 and Lacc1−/− mice were used to establish a mouse model of IBD induced by dextran sodium sulfate (DSS). The effects of Lacc1 deletion in mice were evaluated. Changes in the body weight and stool blood were recorded daily. After 7 days of successful modeling, the mice were sacrificed, blood was collected from the eyeballs, the entire colon was dissected and separated, and the length of the colon was measured.

Results

Compared with the wild-type (WT) DSS model group, the Lacc1−/− DSS model group showed a significantly higher disease activity index score (P < 0.05), significantly faster weight loss (P < 0.05), and a significantly shorter colon (P < 0.05), indicating that the colonic mucosal tissue was seriously damaged in the Lacc1−/− DSS model group (P < 0.05). Serum IL-1β, IL-6, TNF-α, and IFN-γ levels were significantly higher in the Lacc1−/− DSS model group than the WT DSS model group. Principal coordinate analysis showed that there were significant microbiome differences between the WT, Lacc1−/−, WT DSS model, and Lacc1−/− DSS model groups (P < 0.05). Linear discriminant analysis effect size analysis showed that under natural conditions, Lacc1−/− mice had significant changes in their intestinal flora compared with control mice (LDA value > 3 or < 3, P < 0.05).

Conclusions

Lacc1 deletion aggravates DSS-induced IBD in mice.
Literature
2.
go back to reference Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis. Surg Clin North Am. 2019;99:1051–62.CrossRefPubMed Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis. Surg Clin North Am. 2019;99:1051–62.CrossRefPubMed
3.
go back to reference Malik TA. Inflammatory bowel disease: historical perspective, epidemiology, and risk factors. Surg Clin North Am. 2015;95:1105–22.CrossRefPubMed Malik TA. Inflammatory bowel disease: historical perspective, epidemiology, and risk factors. Surg Clin North Am. 2015;95:1105–22.CrossRefPubMed
4.
go back to reference Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–78.CrossRefPubMed Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–78.CrossRefPubMed
5.
6.
go back to reference Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1–10.CrossRefPubMed Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1–10.CrossRefPubMed
7.
go back to reference Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4:293–305.CrossRefPubMed Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4:293–305.CrossRefPubMed
9.
go back to reference Wang K, Xuan XM, Tong L, Huang Q, Zhu LM, Ruan HL. [The role of Treg/Thl7 and calprotectin in ulcerative colitis rat model]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014;45:946–9.PubMed Wang K, Xuan XM, Tong L, Huang Q, Zhu LM, Ruan HL. [The role of Treg/Thl7 and calprotectin in ulcerative colitis rat model]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014;45:946–9.PubMed
10.
go back to reference He Y, Lin LJ, Zheng CQ, Jin Y, Lin Y. Cytokine expression and the role of Thl7 cells in mice colitis. Hepatogastroenterology. 2012;59:1809–13.PubMed He Y, Lin LJ, Zheng CQ, Jin Y, Lin Y. Cytokine expression and the role of Thl7 cells in mice colitis. Hepatogastroenterology. 2012;59:1809–13.PubMed
11.
go back to reference Assadi G, Saleh R, Hadizadeh F, Vesterlund L, Bonfiglio F, Halfvarson J, et al. LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis. Genes Immun. 2016;17:261–4.CrossRefPubMed Assadi G, Saleh R, Hadizadeh F, Vesterlund L, Bonfiglio F, Halfvarson J, et al. LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis. Genes Immun. 2016;17:261–4.CrossRefPubMed
12.
go back to reference Szymanski AM, Ombrello MJ. Using genes to triangulate the pathophysiology of granulomatous autoinflammatory disease: NOD2, PLCG2 and LACC1. Int Immunol. 2018;30:205–13.CrossRefPubMedPubMedCentral Szymanski AM, Ombrello MJ. Using genes to triangulate the pathophysiology of granulomatous autoinflammatory disease: NOD2, PLCG2 and LACC1. Int Immunol. 2018;30:205–13.CrossRefPubMedPubMedCentral
13.
go back to reference Kang JW, Yan J, Ranjan K, Zhang X, Turner JR, Abraham C. Myeloid cell expression of LACC1 is required for bacterial clearance and control of intestinal inflammation. Gastroenterology. 2020;159:1051–67.CrossRefPubMed Kang JW, Yan J, Ranjan K, Zhang X, Turner JR, Abraham C. Myeloid cell expression of LACC1 is required for bacterial clearance and control of intestinal inflammation. Gastroenterology. 2020;159:1051–67.CrossRefPubMed
14.
go back to reference Weber A, Wasiliew P, Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci Signal. 2010;3:cm2.PubMed Weber A, Wasiliew P, Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci Signal. 2010;3:cm2.PubMed
15.
go back to reference Kanamori Y, Murakami M, Sugiyama M, Hashimoto O, Matsui T, Funaba M. Hepcidin and IL-1β. Vitam Horm. 2019;110:143–56.CrossRefPubMed Kanamori Y, Murakami M, Sugiyama M, Hashimoto O, Matsui T, Funaba M. Hepcidin and IL-1β. Vitam Horm. 2019;110:143–56.CrossRefPubMed
16.
go back to reference Wang Y, Che M, Xin J, Zheng Z, Li J, Zhang S. The role of IL-1β and TNF-α in intervertebral disc degeneration. Biomed Pharmacother. 2020;131:110660.CrossRefPubMed Wang Y, Che M, Xin J, Zheng Z, Li J, Zhang S. The role of IL-1β and TNF-α in intervertebral disc degeneration. Biomed Pharmacother. 2020;131:110660.CrossRefPubMed
17.
go back to reference Shao J, Ding Z, Peng J, Zhou R, Li L, Qian Q, et al. MiR-146a-5p promotes IL-1β-induced chondrocyte apoptosis through the TRAF6-mediated NF-kB pathway. Inflamm Res. 2020;69:619–30.CrossRefPubMed Shao J, Ding Z, Peng J, Zhou R, Li L, Qian Q, et al. MiR-146a-5p promotes IL-1β-induced chondrocyte apoptosis through the TRAF6-mediated NF-kB pathway. Inflamm Res. 2020;69:619–30.CrossRefPubMed
18.
19.
go back to reference Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, et al. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol. 2017;13:223–33.CrossRefPubMed Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, et al. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol. 2017;13:223–33.CrossRefPubMed
20.
go back to reference Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16:38–51.CrossRefPubMed Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16:38–51.CrossRefPubMed
21.
go back to reference Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, et al. Reduced abundance of butyrate-producing Bacteria species in the fecal Microbial Community in Crohn’s Disease. Digestion. 2016;93:59–65.CrossRefPubMed Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, et al. Reduced abundance of butyrate-producing Bacteria species in the fecal Microbial Community in Crohn’s Disease. Digestion. 2016;93:59–65.CrossRefPubMed
22.
go back to reference Nishiyama H, Endo H, Blanc-Mathieu R, Ogata H. Ecological structuring of Temperate Bacteriophages in the inflammatory bowel disease-affected gut. Microorganisms. 2020;8. Nishiyama H, Endo H, Blanc-Mathieu R, Ogata H. Ecological structuring of Temperate Bacteriophages in the inflammatory bowel disease-affected gut. Microorganisms. 2020;8.
23.
go back to reference Gagnière J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22:501–18.CrossRefPubMedPubMedCentral Gagnière J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22:501–18.CrossRefPubMedPubMedCentral
Metadata
Title
LACC1 regulates changes in the intestinal flora in a mouse model of inflammatory bowel disease
Authors
Zheng-Yuan Xu
Jin-Chun Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02971-5

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.